ClinicalTrials.Veeva

Menu

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories (EBONI)

ViiV Healthcare logo

ViiV Healthcare

Status and phase

Completed
Phase 4

Conditions

HIV Infections

Treatments

Drug: APRETUDE
Drug: Cabotegravir tablet

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

The purpose of the study is to evaluate the appropriateness, adoption, feasibility, fidelity, and acceptability of implementation strategies and Cabotegravir (CAB) pre-exposure prophylaxis (PrEP). The study objectives are also to identify barriers and facilitators to implementation. The first of two participant types in the study are the Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available CAB PrEP via prescription from the PrEP provider. The second are Staff Study Participants (SSPs) who are site staff involved in the administrative and clinical aspects of offering and administering PrEP to PSPs at the clinical site.

Enrollment

295 patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Participant must be ≥18 years of age, at the time of signing the informed consent.
  • HIV negative at screening. Type of HIV-1 test is per standard of care.
  • No prior history of receiving oral CAB or CAB LA injections.
  • PrEP provider deems CAB PrEP use to be appropriate per the applicable CAB PrEP prescribing information prior to enrollment in the study.
  • Female at birth or self-identified Transgender Female.
  • Self-identified as African American/Black
  • Capable of giving signed informed consent

Exclusion criteria

  • HIV indeterminate or positive test result during screening.
  • A participant of concurrent interventional clinical or implementation science study at any time during the study.
  • Cis-gender or Transgender male

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

295 participants in 3 patient groups

Standard Implementation (SI)
Active Comparator group
Description:
The SI arm evaluated cabotegravir long-acting injectable (CAB LA) for pre-exposure prophylaxis (PrEP) delivery using standard toolkits made available with the commercial release of CAB LA for providers and patients to use as needed, along with implementation monitoring.
Treatment:
Drug: Cabotegravir tablet
Drug: APRETUDE
Enhanced Implementation (EI)
Experimental group
Description:
The EI arm evaluated CAB LA delivery using the standard toolkits plus enhanced supports to use as needed, along with implementation monitoring. EI sites received supports like patient-provider discussion tools, informational tools, and provider education.
Treatment:
Drug: Cabotegravir tablet
Drug: APRETUDE
Enhanced Collaborative Implementation (ECI)
Experimental group
Description:
The ECI arm evaluated CAB LA delivery using the standard toolkits plus enhanced supports to use as needed, along with implementation monitoring. ECI sites received supports like a sexual health assessment, provider education, videos, informational tools, persistence support, and peer ambassadors.
Treatment:
Drug: Cabotegravir tablet
Drug: APRETUDE

Trial documents
5

Trial contacts and locations

22

Loading...

Central trial contact

EU GSK Clinical Trials Call Center; US GSK Clinical Trials Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems